An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (NCT02365597)
A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Sedona, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (105 Sites)
Showing the first 25 of 105 sites.
- Clinical Research Facility — Sedona, Arizona
- Clinical Research Facility — Los Angeles, California
- Clinical Research Facility — Orange, California
- Clinical Research Facility — Sacramento, California
- Clinical Research Facility — Stanford, California
- Clinical Research Facility — Aurora, Colorado
- Clinical Research Facility — Washington D.C., District of Columbia
- Clinical Research Facility — Chicago, Illinois
- Clinical Research Facility — Iowa City, Iowa
- Clinical Research Facility — Louisville, Kentucky
- Clinical Research Facility — Minneapolis, Minnesota
- Clinical Research Facility — Omaha, Nebraska
- Clinical Research Facility — Las Vegas, Nevada
- Clinical Research Facility — New York, New York
- Clinical Research Facility — Charlotte, North Carolina
- Clinical Research Facility — Medford, Oregon
- Clinical Research Facility — Tualatin, Oregon
- Clinical Research Facility — Hershey, Pennsylvania
- Clinical Research Facility — Pittsburgh, Pennsylvania
- Clinical Research Facility — Myrtle Beach, South Carolina
- Clinical Research Facility — Nashville, Tennessee
- Clinical Research Facility — Dallas, Texas
- Clinical Research Facility — Denton, Texas
- Clinical Research Facility — Houston, Texas
- Clinical Research Facility — Hampton, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Cancer
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Chandler, Arizona
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Anchorage, Alaska
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Cleveland, Ohio
- A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Los Angeles, California
Explore by condition: All Urothelial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.